Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Company to Host ASCO Investor & Analyst Reception on Sunday, June 2, 2019 at 6:00 pm CT BURLINGAME, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present initial clinical data from its Phase 1/1b clinical trial of CPI-006 at the American Society of Clinical Oncology ( ASCO ) Annual Meeting in Chicago . Corvus will present data on CPI-006 in an oral presentation and a poster session: Abstract 2505: Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers. Presenter: Jason Luke, M.D., Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center Session Title: Oral Abstract Session: Developmental Immunotherapy and Tumor Immunobiology Date and Time: Sunday, June 2, 2019 from 9:24 am – 9:36 am CT Location: Hall D2 / McCormick Place, Chicago, Illinois Poster 289a: A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers. Presenter: Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer Poster Session: Developmental Immunotherapy and Tumor Immunobiology Date and Time: Saturday, June 1, 2019 from 8:00 am – 11:00 am CT Location: Hall A / McCormick Place, Chicago, Illinois ASCO Investor & Analyst Reception Corvus will host an investor and analyst reception on Sunday, June 2, 2019 at 6:00 pm CT , to discuss the data on CPI-006 presented at ASCO . The reception will feature Dr. Luke along with Richard A. Miller , M.D., president and chief executive officer of Corvus, and Mehrdad Mobasher , M.D., vice president and chief medical officer of Corvus. For information on attending the reception, please reach out to Zack Kubow at [email protected] . There will be live webcast of the reception, which may be accessed via the investor relations section of the Corvus website . A replay of the webcast will be available on Corvus' website for one year. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidate, ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, is currently being evaluated in a multicenter amended Phase 1b/2 clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of ciforadenant both as a single agent and in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group , under a clinical trial collaboration the two companies entered into in October 2015 . In May 2017 , Corvus and Genentech expanded the collaboration and are now conducting a trial of ciforadenant and atezolizumab in patients with non-small cell lung cancer (NSCLC) who have failed prior therapies with anti-PD-(L)1 and platinum-based chemotherapy. Corvus is evaluating two additional product candidates: CPI-006, a humanized monoclonal antibody directed against CD73, in a multicenter Phase 1/1b clinical trial in patients with various solid tumors, and CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com . INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522 [email protected] MEDIA CONTACT: Sheryl Seapy W2O pure +1 213-262-9390 [email protected] Source: Corvus Pharmaceuticals, Inc.

The release as fetched from its publisher. corvuspharma.com ↗